Roche nabbed a first-line approval for Avastin in brain cancer. Japanese regulators cleared the drug to treat aggressive brain tumors, including newly diagnosed glioblastoma, as monotherapy and in combination with radiation and chemo.
Even friends have disputes over money sometimes. That's what's happening with PDL BioPharma and Roche's Genentech: PDL wants to take Genentech to arbitration for underpaying royalties, the AP reports.
Seaside Therapeutics has suffered a string of setbacks recently. Swiss drug giant Roche has passed on taking an option on Cambridge, MA-based Seaside's lead drug candidate arbaclofen, which the biotech startup revealed last month flunked a Phase II autism study and Phase III trial in Fragile X patients.
In the bid to propel personalized medicine into everyday use, Biodesix may have hit pay dirt. The company's recently concluded Phase III trial appears to show that its lung cancer blood diagnostic successfully predicts treatment outcomes for two different therapies.
Here's a roundup of news on approved drugs from this year's American Society of Clinical Oncology conference, comprising highlights from FierceBiotech 's weekend coverage as well as recent releases.
Roche took two steps forward and one step back on the Avastin front today, as investigators laid out a clear advantage in adding the therapy to chemo for cervical cancer while finding no survival advantage when adding it to first-line treatment of an aggressive form of brain cancer.
Indiana devicemakers are among a throng of biotech industry players that has taken up with the state to launch an estimated $360 million public-private research institute to further Indiana's already-thriving biotech industry.
Eli Lilly and Roche Diagnostics have joined an industry consortium that will help launch a new research institute in Indiana that plans to hire a staff of about 100 investigators to pursue new treatments for a slate of metabolic diseases.
Roche Diagnostics has kicked off commercialization for a new bead-based DNA reagent kit, a sequencing tool the company hopes will boost revenue in its flagging research-use technology business.
As Bloomberg reports, Germany's Der Spiegel has ferreted more details about drug research in Soviet-era East Germany, where pharma groups tied to some of the biggest names in the industry reportedly benefited from cheap clinical trials before the fall of the Berlin Wall.